Future Directions of ECMO — Summary

1. Introduction

  • Perspective: Based on reflection of predictions made in 2019 and ongoing clinical experience since 1994.

  • Core Message: ECMO remains a team-driven therapy where progress must be guided by humility and continuous learning.

2. Historical Context and Early Predictions

  • Past Reflection:

    • ECMO in 1988: limited publications, emerging organization (ELSO), early membrane oxygenators, and challenges with case selection and bleeding.

    • Surface coating improved safety but not eliminated need for anticoagulation.

  • 2019 Outlook:

    • Main barriers identified: late initiation, bleeding, ventilator-induced lung injury, and organizational issues.

    • Still largely true in 2025.

3. Lessons from the COVID-19 Pandemic

  • Unexpected Global Event: ECMO proved critical during COVID-19.

  • Collaborative Networks:

    • ELSO and COVID Critical Care Consortium established guidelines and shared data rapidly.

  • Evidence:

    • Meta-analyses confirmed ECMO’s survival benefit for ARDS and COVID-19.

4. Clinical and Technological Evolution

  • Case Selection & Reversibility:

    • Understanding disease reversibility improved survival (example: long-term ECMO survivors).

    • Gene therapy and new drugs emerging; antibiotic resistance may be mitigated by phage therapy.

  • Advances in Support:

    • ECMO as bridge to recovery or transplant.

    • Transition from heparin to bivalirudin reduced bleeding and neurological complications.

    • Improved survival with single ventricle assist devices.

5. Anticipated Innovations

  • Ventilation & Circuit Control:

    • Vision for reduced or eliminated ventilator use.

    • Future includes wearable respiratory assist devices (“RADs”), automated AI-controlled circuits, and robotic cannulation.

  • Technology Expansion:

    • Broader ECMO deployment in emergency departments, ambulances, and military.

    • Use of xenotransplantation, 3D-printed organs, and microfluidic lungs.

    • Enhanced surface coatings (e.g., tethered liquid fluorocarbon) reducing clotting.

    • Artificial placenta therapy may transform neonatal care.

6. Patient-Centered Practice

  • Awake ECMO:

    • Proven feasible since early experiences; promotes recovery and bridges to transplant.

  • Team Challenges:

    • Need to preserve doctor–patient connection amid growing teams and complex electronic records.

7. Conclusion

  • ECMO’s future combines technological precision with human connection.

  • Awake care, AI integration, and organ innovation will shape the next era.

  • The guiding principle: learn from past challenges while embracing innovation with humility and teamwork.

PreviousNext